Asia Pacific Acute Myeloid Leukemia Treatment Market Size & Outlook
The acute myeloid leukemia treatment market in Asia Pacific is expected to reach a projected revenue of US$ 1,581.2 million by 2030. A compound annual growth rate of 11.3% is expected of Asia Pacific acute myeloid leukemia treatment market from 2024 to 2030.
Revenue, 2023 (US$M)
$748.4
Forecast, 2030 (US$M)
$1,581.2
CAGR, 2024 - 2030
11.3%
Report Coverage
Asia Pacific
Asia Pacific acute myeloid leukemia treatment market, 2018-2030 (US$M)
Related Markets
Asia Pacific acute myeloid leukemia treatment market highlights
- The Asia Pacific acute myeloid leukemia treatment market generated a revenue of USD 748.4 million in 2023.
- The market is expected to grow at a CAGR of 11.3% from 2024 to 2030.
- In terms of segment, myeloblastic leukemia was the largest revenue generating disease in 2023.
- Myeloblastic Leukemia is the most lucrative disease segment registering the fastest growth during the forecast period.
Asia Pacific data book summary
| Market revenue in 2023 | USD 748.4 million |
| Market revenue in 2030 | USD 1,581.2 million |
| Growth rate | 11.3% (CAGR from 2023 to 2030) |
| Largest segment | Myeloblastic leukemia |
| Fastest growing segment | Myeloblastic Leukemia |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Myeloblastic Leukemia |
| Key market players worldwide | Astellas Pharma Inc, Bristol-Myers Squibb Co, Celgene, Daiichi Sankyo Co Ltd, Jazz Pharmaceuticals PLC, Novartis AG ADR, Otsuka Pharmaceutical, Pfizer Inc, Rigel Pharmaceuticals Inc, Merck & Co Inc, Sanofi SA |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 23.5% of the global acute myeloid leukemia treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,581.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Acute Myeloid Leukemia Treatment Market Scope
Acute myeloid leukemia treatment market segmentation & scope
Myeloblastic Leukemia
Myelomonocytic Leukemia
Promyelocytic Leukemia
Monocytic Leukemia
Other Diseases
Treatment
Chemotherapy
Targeted Therapy
Immunotherapy
Other Treatments
Route of Administration
Parenteral
Oral
End Use
Hospitals and Clinics
Specialty Centers
Homecare Setting
Ambulatory Care Centers
Countries
U.S.
Canada
Mexico
Denmark
France
Germany
Italy
Norway
Spain
Sweden
UK
China
India
Japan
South Korea
Thailand
Australia
Brazil
Argentina
UAE
South Africa
Saudi Arabia
Kuwait
Acute Myeloid Leukemia Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
